NRF seeks congressional help with job creation
WASHINGTON The National Retail Federation told House Republican leaders Friday that Congress needs to pass legislation that encourages job creation through tax policy and greater availability of credit.
“Our members’ No. 1 issue is job creation,” NRF president and CEO Matt Shay said. “We are willing to talk to anybody about how to create jobs and get the economy back on track. This is not a partisan issue. It’s an economic issue.
The NRF head also cited that retailers employ 1-out-of-5 American workers and consumer spending accounts for two-thirds of the GDP, indicating that “the road to recovery clearly runs through retail.”
“Job recovery needs to be led by the private sector,” Shay added. “We need policies that will help free access to credit so business can begin to expand, prosper and create jobs. That means more certainty in federal tax policy and the regulatory agenda, and fewer mandates that discourage job creation.”
Shay was among executives from more than a dozen business associations who participated in a forum on job creation held at the Capitol by House Minority Leader John Boehner, R-Ohio, and the House GOP’s America Speaking Out program.
‘Preschool is Cool: Counting with Elmo’ arrives on DVD this fall
BURBANK, Calif. Warner Home Video is bringing Sesame Street’s beloved resident, Elmo, to DVD.
“Preschool is Cool: Counting with Elmo” supports such early math skills as number recognition, counting and enumeration with the help of Elmo and his friends.
“Warner Home Video is very happy to introduce ‘Counting with Elmo, ‘our newest DVD title in Sesame Street’s new DVD set ‘Preschool is Cool,’” said Amit Desai, WHV VP family animation and partner brands marketing. “Counting is an essential tool that every preschooler must learn and there’s nobody better than the beloved Elmo and Professor Grover to show kids how fun and exciting numbers can be.”
“Preschool is Cool: Counting with Elmo” is available on DVD Sept. 14, for a suggested retail priceof $14.98.
Keryx gets orphan-drug designation for neuroblastoma treatment
NEW YORK The Food and Drug Administration has given special designation to an investigational treatment for a cancer of the nervous system that affects children.
Keryx Biopharmaceuticals announced Wednesday that it received orphan drug designation for KRX-0401 (perifosine), a treatment for neuroblastoma. No FDA-approved treatments exist for the disease.
The FDA gives orphan drug designation to investigational treatments for rare illnesses or those affecting fewer than 200,000 patients in the United States. The designation entitles the drug maker to seven years’ market exclusivity following approval, tax benefits and exemption from certain application filing fees.